Abstract
Janus kinase inhibitors (JAKs) are small molecules capable of blocking cytokine signal transduction at the intracellular level. There are currently two products available in the Czech Republic: tofacitinib and baricitinib.
According to the recommendation of the Czech Rheumatological Society, CLS JEP may be administered in patients with rheumatoid arthritis after failure of methotrexate or biological therapy. The efficacy of JAK inhibitors is comparable to biological agents against which they have several advantages.
The main drawback of JAK inhibitors compared to biological therapy is the less clinical experience and the consequent lesser scope of safety data on long-term use of these drugs.